A Look At Quest Diagnostics (DGX) Valuation As Shares Trade Below Fair Value Estimate

Event context and recent stock moves

Quest Diagnostics (DGX) shares recently traded around $198.61, with the stock showing a 0.2% decline over the past day and a 1.1% decline over the past week, while remaining higher over the past 3 months.

See our latest analysis for Quest Diagnostics.

While the share price has seen a 4.0% decline over the past month, momentum over a longer horizon remains positive, with a 10.9% 3 month share price return and a 17.3% 1 year total shareholder return suggesting sentiment has been improving rather than fading.

If recent healthcare moves have caught your attention, it can be useful to see how other medical names are trading via a focused screener such as 36 healthcare AI stocks.

With Quest Diagnostics trading around $198.61, positive 1 year returns and some discount to both analyst targets and intrinsic value estimates raise the key question for you: is there still a buying opportunity here, or has the market already priced in future growth?

Most Popular Narrative: 9.1% Undervalued

Quest Diagnostics latest fair value estimate of $218.50 sits above the recent $198.61 share price, which puts the current analyst narrative under the spotlight.

The rising importance of health data analytics and Quest's role as a lab engine for consumer wellness brands positions the company to benefit from new revenue streams and further monetization opportunities as healthcare becomes more data driven, supporting long term earnings power.

Read the complete narrative.

Curious what kind of revenue path and margin profile need to line up for that valuation to make sense? The underlying model leans heavily on steady volume gains, richer test mix and a premium earnings multiple that assumes investors keep treating Quest as a quality anchor in diagnostics.

Using a 6.98% discount rate, the narrative ties that fair value to moderate revenue growth, firmer profit margins and a P/E that sits above many broad market names but is framed as reasonable for a large US healthcare testing group. It also assumes Quest can keep earnings growing while returning capital to shareholders through buybacks and dividends without stretching its balance sheet.

Result: Fair Value of $218.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, it is still important to keep an eye on potential PAMA reimbursement cuts and rising wage and technology costs, which could pressure Quest’s revenue growth and margin assumptions.

Find out about the key risks to this Quest Diagnostics narrative.

Next Steps

With sentiment clearly mixed, and with both risks and rewards in play, it makes sense to move quickly and stress test the story for yourself using 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

Do not stop your research with just one healthcare name, broaden your watchlist with fresh ideas that match your risk, income, and quality preferences.

• Target steadier return profiles by scanning 77 resilient stocks with low risk scores to find options that aim to keep drawdowns more controlled while still offering equity upside.
• Hunt for potential mispriced businesses through the screener containing 27 high quality undiscovered gems and spot companies that the crowd may not be focusing on yet.
• Strengthen the quality of your core holdings by filtering for companies in the solid balance sheet and fundamentals stocks screener (42 results) that pair financial resilience with fundamental support.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com